Complex Regional Pain Syndrome (CRPS) is a chronic condition that causes severe pain in legs, arms, feet, and hands or may involve the entire body. CRPS is commonly of two types, with similar symptoms and treatment. If Complex Regional Pain syndrome occurs after an injury without any nerve damage, it is known as Type I CRPS (also known as reflex sympathetic dystrophy). Type II CRPS occurs after a specific nerve injury or trauma. The prognosis of complex regional pain syndrome differs from person to person. In most cases, CRPS is mild and patient recovers gradually with time, and in some cases, the symptoms are severe, with long-term disability. CRPS occurs in both men and women, but women are more likely to be affected.
The cause of the Complex Regional Pain Syndrome (CRPS) is not well understood. In about 90% of cases, CRPS occurs due to injury or trauma. The common factor of injury includes limb immobilization, soft tissue injury, fracture, sprain or due to needlestick injuries caused during surgical procedures. Peripheral nerve abnormalities in patients with CRPS includes unmyelinated and lightly myelinated nerve fibers at the axon region that causes abnormal neurological conditions. CRPS is common in patients with inflammatory and autoimmune conditions as an elevated level of inflammatory chemicals such as cytokines are found in tissue with CRPS. Currently, genetic predisposition of Complex Regional Pain Syndrome is not examined broadly. A study related to the familial occurrence of CRPS among Dutch patients resulted that CRPS may occur in a familial form, but inheritance pattern was unclear.
Diagnosis of CRPS depends upon the individual’s medical history and the extent of symptoms. There are limited diagnostic methods available for CRPS. The incidence rates reveal that female are three times more affected than male. According to a study conducted in U.K, 1 in 3,800 people develops CRPS each year. CRPS can be treated by therapy (Rehabilitation Therapy, Psychotherapy) or medications such as non-steroidal anti-inflammatory drugs, corticosteroids, and others.
Request Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1708
Complex Regional Pain syndrome (CRPS) Market: Drivers and Restrains
Currently, there are no drugs approved by US FDA – for the treatment of Complex Regional Pain Syndrome. However, physicians prescribed therapies and medicines to alleviate chronic pain. Recently U.S. Food and Drug administration, designated Neridronic acid breakthrough therapy, undergoing clinical trials for Complex Regional Pain Syndrome. The drug has also received Fast-track and orphan drug designations from the FDA. Intense research and development, the rise in the incidence of CRPS cases, successful completion of clinical trials are anticipated to fuel the growth of Complex Regional Pain Syndrome. The strict regulatory approval and the high cost of medication in the near future could restrain the growth of Complex Regional Pain syndrome market.
Complex Regional Pain syndrome (CRPS) Market: Overview
National Institutes of Health (NIH) is supporting research for CRPS on the brain and CNS by focusing on studying new approaches in treating CRPS. Based on the therapy type the global Complex Regional Pain syndrome (CRPS) market into physical therapy, drugs such as analgesics, antidepressants, corticosteroids, surgical sympathectomy, intrathecal drug pumps and spinal cord stimulation. On the basis of route of administration, the global Complex Regional Pain syndrome (CRPS) market in segmented into oral and intravenous administration. Based on the distribution channel, the market is segmented into hospital pharmacy, drug stores, retain pharmacy and e-commerce.
Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1708
Complex Regional Pain syndrome (CRPS) Market: Regional Overview
Region wise, the global Complex Regional Pain syndrome (CRPS) market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. Along with expansion in the emerging markets, and greater focus on early diagnosis, screening, monitoring and clinical development of drugs have been the major strategies adopted by major players in the global complex regional pain syndrome (CRPS) market.
Complex Regional Pain syndrome (CRPS) Market: Key Players
Some of the key players in global complex regional pain syndrome (CRPS) market are Mallinckrodt Pharmaceutical, GlaxoSmithKline plc., Mylan N.V., Teva Pharmaceutical Industries Ltd., AbbVie, ACTAVIS, Zydus Pharmaceuticals, Inc., Sandoz, and Janssen Global Services, LLC.and others.